Literature DB >> 29870077

Diagnosis of concomitant inducible laryngeal obstruction and asthma.

Joy W Lee1,2, Tunn Ren Tay3, Paul Paddle4,5, Amanda L Richards6, Lisa Pointon7, Miriam Voortman7, Michael J Abramson1, Ryan Hoy1,2, Mark Hew1,2.   

Abstract

BACKGROUND: Inducible laryngeal obstruction, an induced, inappropriate narrowing of the larynx, leading to symptomatic upper airway obstruction, can coexist with asthma. Accurate classification has been challenging because of overlapping symptoms and the absence of sensitive diagnostic criteria for either condition.
OBJECTIVE: To evaluate patients with concomitant clinical suspicion for inducible laryngeal obstruction and asthma. We used a multidisciplinary protocol incorporating objective diagnostic criteria to determine whether asthma, inducible laryngeal obstruction, both, or neither diagnosis was present.
METHODS: Consecutive patients were prospectively assessed by a laryngologist, speech pathologist and respiratory physician. Inducible laryngeal obstruction was diagnosed by visualizing paradoxical vocal fold motion either at baseline or following mannitol provocation. Asthma was diagnosed by physician assessment with objective variable airflow obstruction. Validated questionnaires for laryngeal dysfunction and relevant comorbidities were administered.
RESULTS: Of 69 patients, 15 had asthma alone, 11 had inducible laryngeal obstruction alone and 14 had neither objectively demonstrated. Twenty-nine patients had both diagnoses. In 19 patients, inducible laryngeal obstruction was only seen following provocation. Among patients with inducible laryngeal obstruction, chest tightness was more frequent with concurrent asthma. Among patients with asthma, stridor was more frequent with concurrent inducible laryngeal obstruction. Cough was more frequently found in asthma alone, whereas difficulty with inspiration and symptoms triggered by psychological stress were more frequently found in inducible laryngeal obstruction alone. Patients with asthma alone had greater airflow obstruction. Relevant comorbidities were frequent (rhinitis in 85%, gastro-oesophageal reflux in 65%), and questionnaire scores for laryngeal dysfunction were abnormal. However, neither comorbidities nor questionnaires differentiated patients with or without inducible laryngeal obstruction. CONCLUSIONS AND CLINICAL RELEVANCE: In this cohort with suspected inducible laryngeal obstruction and asthma, 42% had objective evidence of both conditions. Clinical assessment, questionnaire scores and comorbidity burden were not sufficiently discriminatory for diagnosis, highlighting the necessity of objective diagnostic testing.
© 2018 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma; inducible laryngeal obstruction; larynx; mannitol; paradoxical vocal fold motion

Mesh:

Year:  2018        PMID: 29870077     DOI: 10.1111/cea.13185

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  4 in total

1.  The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children.

Authors:  Jonathan M Gaffin; Mario Castro; Leonard B Bacharier; Anne L Fuhlbrigge
Journal:  J Allergy Clin Immunol Pract       Date:  2021-12-01

2.  Systematic review of the effectiveness of non-pharmacological interventions used to treat adults with inducible laryngeal obstruction.

Authors:  Jemma Haines; Jacklyn Ann Smith; James Wingfield-Digby; Jenny King; Janelle Yorke; Stephen J Fowler
Journal:  BMJ Open Respir Res       Date:  2022-06

3.  Feasibility of portable continuous laryngoscopy during exercise testing.

Authors:  James H Hull; Emil S Walsted; Christopher M Orton; Parris Williams; Simon Ward; Mathew J Pavitt
Journal:  ERJ Open Res       Date:  2019-02-04

4.  Asthma in Competitive Cross-Country Skiers: A Systematic Review and Meta-analysis.

Authors:  Rikhard Mäki-Heikkilä; Jussi Karjalainen; Jari Parkkari; Maarit Valtonen; Lauri Lehtimäki
Journal:  Sports Med       Date:  2020-11       Impact factor: 11.136

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.